This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first Humira biosimilar hit the U.S. market a little ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

The Biosimilars Council, a trade association representing manufacturers of biosimilar medicines, released a new analysis of IQVIA data revealing health plans and patients missed out on savings up to ...

Late last week, Amgen and AbbVie settled litigation over when competition for the world’s best-selling biologic Humira (adalimumab) will hit the market, and for the US, the settlement decided on 31 ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...

Blue Shield of California has cut the price it will pay for a biosimilar of the drug Humira. Blue Shield will purchase the medicine used to treat certain autoimmune and inflammatory diseases, such as ...

(Reuters) - AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...